Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 28 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Suven Pharmaceuticals Ltd

About the Company - Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24299TG2018PLC128171 and registration number is 128171. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1320.22 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2022.
Pharmaceuticals8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Hyderabad Telangana
NamePosition Held
Mr. Annaswamy VaidheeshExecutive Chairman
Mr. V Prasada RajuManaging Director
Mr. Pankaj PatwariNon Exe.Non Ind.Director
Ms. Shweta JalanNon Exe.Non Ind.Director
Ms. Matangi GowrishankarIndependent Director
Mr. Vinod RaoIndependent Director
Mr. K G AnanthakrishnanIndependent Director
Mr. Pravin Rao Udhyavara Bhadya#Independent Director

Suven Pharmaceuticals Ltd. Share Price Update

Share PriceValue
Previous Day₹663.55

Basic Stock Data of Suven Pharmaceuticals Ltd

Market Cap 16,752 Cr.
Current Price 658
High / Low768/375
Stock P/E45.2
Book Value 76.0
Dividend Yield0.15 %
ROCE32.5 %
ROE24.5 %
Face Value 1.00

Data Source:

Competitors of Suven Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Caplin Point Laboratories Ltd 11,887 Cr. 1,5651,619/57527.2 2730.28 %26.3 %25.6 % 2.00
Brooks Laboratories Ltd 319 Cr. 122186/56.5 30.10.00 %27.7 %23.4 % 10.0
Themis Medicare Ltd 2,236 Cr. 243254/10949.4 39.60.21 %19.7 %17.3 % 1.00
Torrent Pharmaceuticals Ltd 88,309 Cr. 2,6092,700/1,44661.7 1980.85 %19.8 %20.0 % 5.00
Vaishali Pharma Ltd 168 Cr. 159204/11528.8 41.80.00 %21.7 %19.7 % 10.0
Industry Average20,583.80 Cr939.6033.42116.500.27%23.04%21.20%5.60

Suven Pharmaceuticals Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit981379411512218615715110014716916798
OPM %41%50%36%43%40%48%43%45%36%41%46%48%42%
Other Income9212229226517111113111120
Profit before tax9714810513313423916114998146166164105
Tax %24%23%21%21%28%33%43%28%27%26%25%26%25%
Net Profit741148310597160921087210812412180
EPS in Rs2.914.463.274.133.816.293.604.222.834.234.874.743.13

Suven Pharmaceuticals Ltd Quarterly Chart

Suven Pharmaceuticals Ltd Profit & Loss

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit172385443582574581
OPM %45%46%44%44%43%45%
Other Income166681334655
Profit before tax158405468668560582
Tax %31%22%23%32%27%
Net Profit109317362454411432
EPS in Rs5,463.5012.4514.2317.8316.1616.97
Dividend Payout %-0%20%14%28%37%

Suven Pharmaceuticals Ltd Profit & Loss Yearly Chart

Suven Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:%
3 Years:17%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:9%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:11%
1 Year:38%
Return on Equity
10 Years:%
5 Years:%
3 Years:29%
Last Year:25%

Suven Pharmaceuticals Ltd Balance Sheet

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital01325252525
Other Liabilities123142151205160134
Total Liabilities7831,1731,4741,8301,9662,120
Fixed Assets271357441534663651
Other Assets394376395667601527
Total Assets7831,1731,4741,8301,9662,120

Suven Pharmaceuticals Ltd Reserves and Borrowings Chart

Suven Pharmaceuticals Ltd Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 50407383330451
Cash from Investing Activity -65-413-311-136-195
Cash from Financing Activity 267-76-156-236
Net Cash Flow111-53720

Suven Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days14251376530
Inventory Days556278243259279
Days Payable1901131009758
Cash Conversion Cycle509217180228251
Working Capital Days28510595126117
ROCE %50%40%41%32%

Suven Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Suven Pharmaceuticals Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
No. of Shareholders75,20792,66996,53286,44785,72586,08882,57779,41272,88572,16773,71570,052

Suven Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Suven Pharmaceuticals Ltd Shareholders

Suven Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
UTI Flexi Cap Fund49692141.36359.17
DSP Healthcare Fund25106908.97181.47
HSBC Small Cap Fund - Regular Plan22980851.26166.11
DSP ELSS Tax Saver Fund20694531.1149.58
Tata Small Cap Fund20000002.48144.56
UTI Value Fund16784991.43121.32
Canara Robeco Small Cap Fund16759831.32121.14
DSP Equity Opportunities Fund15397021.07111.29
DSP Flexi Cap Fund13550020.9797.94
HSBC Midcap Fund13402001.0596.87

Suven Pharmaceuticals Ltd ROCE Trend

Suven Pharmaceuticals Ltd EPS Trend

Suven Pharmaceuticals Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)16.1617.8314.2324.918.59
Diluted EPS (Rs.)16.1617.8314.2324.918.59
Cash EPS (Rs.)18.0317.7513.3722.999.49
Book Value[Excl.RevalReserv]/Share (Rs.)68.1659.9946.3966.3746.38
Book Value[Incl.RevalReserv]/Share (Rs.)68.1659.9946.3966.3746.38
Revenue From Operations / Share (Rs.)52.6551.8639.6665.5129.68
PBDIT / Share (Rs.)24.0826.3917.8631.6813.53
PBIT / Share (Rs.)22.2024.8516.6229.8112.62
PBT / Share (Rs.)21.9924.6116.2627.9912.40
Net Profit / Share (Rs.)16.1616.2112.1221.128.59
NP After MI And SOA / Share (Rs.)16.1617.8314.2324.918.59
PBDIT Margin (%)45.7250.8845.0348.3645.56
PBIT Margin (%)42.1647.9241.9045.4942.52
PBT Margin (%)41.7647.4540.9942.7341.78
Net Profit Margin (%)30.6831.2530.5632.2328.92
NP After MI And SOA Margin (%)30.6834.3735.8838.0128.92
Return on Networth / Equity (%)23.7029.7130.6837.5218.51
Return on Capital Employeed (%)31.2739.0733.7139.0125.68
Return On Assets (%)20.9224.8024.5727.0213.95
Long Term Debt / Equity (X)
Total Debt / Equity (X)
Asset Turnover Ratio (%)0.710.800.790.880.00
Current Ratio (X)6.375.362.571.952.47
Quick Ratio (X)4.404.021.661.081.48
Inventory Turnover Ratio (X)1.441.901.651.450.00
Dividend Payout Ratio (NP) (%)0.0022.437.0220.0717.47
Dividend Payout Ratio (CP) (%)0.0020.656.4618.6715.80
Earning Retention Ratio (%)0.0077.5792.9879.9382.53
Cash Earning Retention Ratio (%)0.0079.3593.5481.3384.20
Interest Coverage Ratio (X)112.74107.8249.7317.4861.72
Interest Coverage Ratio (Post Tax) (X)76.6667.2334.7512.6540.18
Enterprise Value (Cr.)12034.4415779.1112742.732735.310.00
EV / Net Operating Revenue (X)8.9811.9512.623.280.00
EV / EBITDA (X)19.6423.4928.026.780.00
MarketCap / Net Operating Revenue (X)8.9811.9212.493.080.00
Retention Ratios (%)0.0077.5692.9779.9282.52
Price / BV (X)6.9310.3010.683.040.00
Price / Net Operating Revenue (X)8.9811.9212.493.080.00

Suven Pharmaceuticals Ltd Profitability Ratios (%)

Suven Pharmaceuticals Ltd Liquidity Ratios

Suven Pharmaceuticals Ltd Liquidity Ratios (%)

Suven Pharmaceuticals Ltd Interest Coverage Ratios (X)

Suven Pharmaceuticals Ltd Valuation Ratios

Fair Value / Intrinsic Value of Suven Pharmaceuticals Ltd

Fair Value: ₹842.89

The stock is undervalued by 28.10% compared to the current price ₹658

*Investments are subject to market risks

Strength and Weakness of Suven Pharmaceuticals Ltd

  1. The stock has a high average ROCE of 32.60%, which is a positive sign.
  2. The company has higher reserves (1,281.17 cr) compared to borrowings (105.00 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (202.67 cr) and profit (473.50 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 21.22 and average Dividend Yield of 44.00%.
  2. The stock has a high average Working Capital Days of 145.60, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 277.00, which may not be favorable.

Should I Buy Suven Pharmaceuticals Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Suven Pharmaceuticals Ltd:
    1. Net Profit Margin: 30.68%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 31.27% (Industry Average ROCE: 23.04%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): 76.66
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 4.40
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✗ Stock P/E: 45.2 (Industry average Stock P/E: 33.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.03
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Suven Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE